About the Company
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRUS News
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license ...
Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Merus N.V. (NASDAQ:MRUS) is definitely a biotech to keep an eye on in the 1st half of 2024. That's because there are two potential catalysts that, I believe, could cause its stock price to trade ...
Merus NV (2GH.DU)
Merus ( NASDAQ:MRUS ) Full Year 2023 Results Key Financial Results Revenue: US$43.9m (up 5.7% from FY 2022). Net loss... Simply Wall St. Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And ...
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), a clinical-stage oncology ...
BMO lifts Merus shares price target to $58 on clinical data confidence
Thursday - BMO Capital Markets has updated its outlook on Merus N.V. (NASDAQ:MRUS), increasing the price target to $58 from the previous $49 while maintaining an Outperform rating. This adjustment ...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...
Gilead Sciences, Merus collaborate to discover novel antibody-based trispecific T-cell engagers
Gilead Sciences, Inc. and Merus N.V. have announced a research collaboration, option and license agreement to discover novel ...
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg ...
Merus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Feb. 28, 2024(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...
Loading the latest forecasts...